{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:10:51Z","timestamp":1789690251129,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,7,26]],"date-time":"2008-07-26T00:00:00Z","timestamp":1217030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s11060-008-9655-9","type":"journal-article","created":{"date-parts":[[2008,7,25]],"date-time":"2008-07-25T03:03:38Z","timestamp":1216955018000},"page":"229-235","source":"Crossref","is-referenced-by-count":32,"title":["A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme"],"prefix":"10.1007","volume":"90","author":[{"given":"Camilo E.","family":"Fadul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Kingman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise P.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard F.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford J.","family":"Eskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Harker","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert B.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Marc","family":"Pipas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,7,26]]},"reference":[{"key":"9655_CR1","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/cncr.11666","volume":"98","author":"RE McLendon","year":"2003","unstructured":"McLendon RE, Halperin EC (2003) Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 98:1745\u20131748. doi: 10.1002\/cncr.11666","journal-title":"Cancer"},{"key":"9655_CR2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. doi: 10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"9655_CR3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0140-6736(00)02586-1","volume":"356","author":"R Govindarajan","year":"2000","unstructured":"Govindarajan R, Heaton KM, Broadwater R et al (2000) Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 356:566\u2013567. doi: 10.1016\/S0140-6736(00)02586-1","journal-title":"Lancet"},{"key":"9655_CR4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s002800050592","volume":"39","author":"S Nakatsu","year":"1997","unstructured":"Nakatsu S, Kondo S, Kondo Y et al (1997) Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 39:417\u2013423. doi: 10.1007\/s002800050592","journal-title":"Cancer Chemother Pharmacol"},{"key":"9655_CR5","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","volume":"17","author":"HS Friedman","year":"1999","unstructured":"Friedman HS, Petros WP, Friedman AH et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516\u20131525","journal-title":"J Clin Oncol"},{"key":"9655_CR6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1215\/S1152851703000292","volume":"6","author":"MD Prados","year":"2004","unstructured":"Prados MD, Yung WK, Jaeckle KA et al (2004) Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol 6:44\u201354. doi: 10.1215\/S1152851703000292","journal-title":"Neuro-oncol"},{"key":"9655_CR7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1215\/S1152851703000218","volume":"6","author":"TT Batchelor","year":"2004","unstructured":"Batchelor TT, Gilbert MR, Supko JG et al (2004) Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro-oncol 6:21\u201327. doi: 10.1215\/S1152851703000218","journal-title":"Neuro-oncol"},{"key":"9655_CR8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1215\/15228517-2005-010","volume":"8","author":"MD Prados","year":"2006","unstructured":"Prados MD, Lamborn K, Yung WK et al (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol 8:189\u2013193. doi: 10.1215\/15228517-2005-010","journal-title":"Neuro-oncol"},{"key":"9655_CR9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/ctrv.2000.0188","volume":"26","author":"SV Rajkumar","year":"2000","unstructured":"Rajkumar SV, Witzig TE (2000) A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26:351\u2013362. doi: 10.1053\/ctrv.2000.0188","journal-title":"Cancer Treat Rev"},{"key":"9655_CR10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1200\/JCO.2000.18.4.708","volume":"18","author":"HA Fine","year":"2000","unstructured":"Fine HA, Figg WD, Jaeckle K et al (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708\u2013715","journal-title":"J Clin Oncol"},{"key":"9655_CR11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1012554328801","volume":"54","author":"GM Marx","year":"2001","unstructured":"Marx GM, Pavlakis N, McCowatt S et al (2001) Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 54:31\u201338. doi: 10.1023\/A:1012554328801","journal-title":"J Neurooncol"},{"key":"9655_CR12","first-page":"23","volume":"16","author":"R Govindarajan","year":"2002","unstructured":"Govindarajan R (2002) Irinotecan\/thalidomide in metastatic colorectal cancer. Oncology (Huntingt) 16:23\u201326","journal-title":"Oncology (Huntingt)"},{"key":"9655_CR13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jchromb.2005.05.010","volume":"821","author":"X Yang","year":"2005","unstructured":"Yang X, Hu Z, Chan SY et al (2005) Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. J Chromatogr B Anal Technol Biomed Life Sci 821:221\u2013228. doi: 10.1016\/j.jchromb.2005.05.010","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"9655_CR14","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2003.08.045","volume":"21","author":"HA Fine","year":"2003","unstructured":"Fine HA, Wen PY, Maher EA et al (2003) Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21:2299\u20132304. doi: 10.1200\/JCO.2003.08.045","journal-title":"J Clin Oncol"},{"key":"9655_CR15","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277\u20131280","journal-title":"J Clin Oncol"},{"key":"9655_CR16","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","volume":"17","author":"ET Wong","year":"1999","unstructured":"Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572\u20132578","journal-title":"J Clin Oncol"},{"key":"9655_CR17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1212\/01.WNL.0000133398.11870.9A","volume":"63","author":"MC Wit de","year":"2004","unstructured":"de Wit MC, de Bruin HG, Eijkenboom W et al (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63:535\u2013537","journal-title":"Neurology"},{"key":"9655_CR18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1215\/15228517-2007-060","volume":"10","author":"VK Puduvalli","year":"2008","unstructured":"Puduvalli VK, Giglio P, Groves MD et al (2008) Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro-oncol 10:216\u2013222. doi: 10.1215\/15228517-2007-060","journal-title":"Neuro-oncol"},{"key":"9655_CR19","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/cncr.11306","volume":"97","author":"TF Cloughesy","year":"2003","unstructured":"Cloughesy TF, Filka E, Kuhn J et al (2003) Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 97:2381\u20132386. doi: 10.1002\/cncr.11306","journal-title":"Cancer"},{"key":"9655_CR20","first-page":"2940","volume":"9","author":"MR Gilbert","year":"2003","unstructured":"Gilbert MR, Supko JG, Batchelor T et al (2003) Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9:2940\u20132949","journal-title":"Clin Cancer Res"},{"key":"9655_CR21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1014532202188","volume":"56","author":"MC Chamberlain","year":"2002","unstructured":"Chamberlain MC (2002) Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 56:183\u2013188. doi: 10.1023\/A:1014532202188","journal-title":"J Neurooncol"},{"key":"9655_CR22","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1038\/sj.onc.1206958","volume":"22","author":"AA Desai","year":"2003","unstructured":"Desai AA, Innocenti F, Ratain MJ (2003) Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene 22:6621\u20136628. doi: 10.1038\/sj.onc.1206958","journal-title":"Oncogene"},{"key":"9655_CR23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01213011-200505000-00004","volume":"15","author":"F Innocenti","year":"2005","unstructured":"Innocenti F, Liu W, Chen P et al (2005) Haplotypes of variants in the UDP-glucuronosyl transferase 1A9 and 1A1 genes. Pharmacogenet Genomics 15:295\u2013301. doi: 10.1097\/01213011-200505000-00004","journal-title":"Pharmacogenet Genomics"},{"key":"9655_CR24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1023\/B:NEON.0000014549.77646.f6","volume":"66","author":"RJ Parker","year":"2004","unstructured":"Parker RJ, Fruehauf JP, Mehta R et al (2004) A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neurooncol 66:365\u2013375. doi: 10.1023\/B:NEON.0000014549.77646.f6","journal-title":"J Neurooncol"},{"key":"9655_CR25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1006414804835","volume":"51","author":"SC Short","year":"2001","unstructured":"Short SC, Traish D, Dowe A et al (2001) Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol 51:41\u201345. doi: 10.1023\/A:1006414804835","journal-title":"J Neurooncol"},{"key":"9655_CR26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijrobp.2004.04.023","volume":"60","author":"SM Chang","year":"2004","unstructured":"Chang SM, Lamborn KR, Malec M et al (2004) Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60:353\u2013357. doi: 10.1016\/j.ijrobp. 2004.04.023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9655_CR27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-006-9225-y","volume":"81","author":"MD Groves","year":"2007","unstructured":"Groves MD, Puduvalli VK, Chang SM et al (2007) A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81:271\u2013277. doi: 10.1007\/s11060-006-9225-y","journal-title":"J Neurooncol"},{"key":"9655_CR28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jpba.2005.02.041","volume":"39","author":"X Yang","year":"2005","unstructured":"Yang X, Hu Z, Chan SY et al (2005) Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat. J Pharm Biomed Anal 39:299\u2013304. doi: 10.1016\/j.jpba.2005.02.041","journal-title":"J Pharm Biomed Anal"},{"key":"9655_CR29","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/cncr.22239","volume":"107","author":"SE Krown","year":"2006","unstructured":"Krown SE, Niedzwiecki D, Hwu WJ et al (2006) Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 107:1883\u20131890. doi: 10.1002\/cncr.22239","journal-title":"Cancer"},{"key":"9655_CR30","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1080\/10428190600799631","volume":"47","author":"KC Miller","year":"2006","unstructured":"Miller KC, Padmanabhan S, Dimicelli L et al (2006) Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma 47:2339\u20132343. doi: 10.1080\/10428190600799631","journal-title":"Leuk Lymphoma"},{"key":"9655_CR31","first-page":"658","volume":"4","author":"M Zangari","year":"2006","unstructured":"Zangari M (2006) Anticoagulation regimens for thalidomide and lenalidomide. Clin Adv Hematol Oncol 4:658\u2013659","journal-title":"Clin Adv Hematol Oncol"},{"key":"9655_CR32","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","volume":"354","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079\u20132080. doi: 10.1056\/NEJMc053530","journal-title":"N Engl J Med"},{"key":"9655_CR33","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","volume":"354","author":"R Knight","year":"2006","unstructured":"Knight R, DeLap RJ, Zeldis JB (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079\u20132080. doi: 10.1056\/NEJMc053530","journal-title":"N Engl J Med"},{"key":"9655_CR34","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ajh.20625","volume":"81","author":"N Ikhlaque","year":"2006","unstructured":"Ikhlaque N, Seshadri V, Kathula S et al (2006) Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 81:420\u2013422. doi: 10.1002\/ajh.20625","journal-title":"Am J Hematol"},{"key":"9655_CR35","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4065\/80.12.1549","volume":"80","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV (2005) Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 80:1549\u20131551","journal-title":"Mayo Clin Proc"},{"key":"9655_CR36","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","volume":"80","author":"R Baz","year":"2005","unstructured":"Baz R, Li L, Kottke-Marchant K et al (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80:1568\u20131574","journal-title":"Mayo Clin Proc"},{"key":"9655_CR37","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/sj.leu.2403533","volume":"18","author":"MC Minnema","year":"2004","unstructured":"Minnema MC, Breitkreutz I, Auwerda JJ et al (2004) Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18:2044\u20132046. doi: 10.1038\/sj.leu.2403533","journal-title":"Leukemia"},{"key":"9655_CR38","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1212\/01.wnl.0000208958.29600.87","volume":"66","author":"WB Pope","year":"2006","unstructured":"Pope WB, Lai A, Nghiemphu P et al (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258\u20131260. doi: 10.1212\/01.wnl.0000208958.29600.87","journal-title":"Neurology"},{"key":"9655_CR39","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722\u20134729. doi: 10.1200\/JCO.2007.12.2440","journal-title":"J Clin Oncol"},{"key":"9655_CR40","author":"TY Kang","year":"2008","unstructured":"Kang TY, Jin T, Elinzano H et al (2008) Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol. doi: 10.1007\/s11060-008-9599-0","journal-title":"J Neurooncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-008-9655-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-008-9655-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-008-9655-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:19:22Z","timestamp":1559348362000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-008-9655-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,26]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["9655"],"URL":"https:\/\/doi.org\/10.1007\/s11060-008-9655-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,26]]}}}